Aytu biopharma announces approval of the cotempla xr-odt(r) manufacturing site transfer prior approval supplement

U.s. food & drug administration approval of the prior approval supplement (pas) enables transfer of cotempla production to contract manufacturer upon completion of manufacturing transfer of adzenys xr-odt and cotempla xr-odt, company expects to report enhanced adhd product margins denver, co / accesswire / october 26, 2023 / aytu biopharma, inc. (the company or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, announced receipt of u.s. food & drug administration (fda) approval of the cotempla xr-odt® ("cotempla") prior approval supplement (pas). this approval enables the transfer of manufacturing of cotempla to the company's third-party manufacturer and follows a similar achievement for adzenys xr- odt® ("adzenys") which received pas approval in april 2023.
AYTU Ratings Summary
AYTU Quant Ranking